Alzheimer’s Diagnostics: The Critical Role of Specimen Quality, Longitudinality & Data Depth
Accurate research relies on the quality and relevance of biospecimens that are utilized. Using Alzheimer’s disease (AD) as an example, Dr. Cathie Miller will discuss how a foundation of high-quality, rigorously characterized biospecimens are building the future of AD diagnostics. The current AD diagnostic revolution relies on accessible blood-based biomarkers like pTau217 and pTau181 to bridge the global detection gap. However, valid clinical implementation demands more than just new assays. Success hinges on three pillars: pre-analytical rigor to ensure biomarker stability, longitudinal tracking to map disease progression, and comprehensive metadata to address health disparities. Progress can be accelerated by integrating matched plasma-CSF sets and multi-timepoint collections that track donors over years. Furthermore, ethnically diverse cohorts and strictly controlled raw materials enable researchers to harmonize assays, validate clinical cutoffs, and ensure diagnostics work for all populations. These specialized resources provide the essential infrastructure to transform promising biomarkers into widely available diagnostic tools. Download the slides: https://bioivt.com/educational-conten... Additional resources on this topic: https://bioivt.com/resources/educatio... Questions, comments and requests: https://bioivt.com/about/contact-us Access BioIVT's biospecimens: https://bioivt.com/products Other previously aired webinars: https://bioivt.com/educational-conten...) Upcoming webinar notifications: https://bioivt.com/resources/newslett... About the presenter Cathie Miller, PhD, is Senior Director of Product Management at BioIVT, which enables smarter science and accelerates medical breakthroughs by delivering high-quality personalized biospecimen solutions and research services to the life science and diagnostic industries. Dr. Miller has more than 20 years of experience as a bench scientist, director, and global product manager, focused on using biospecimens to advance cancer, immunology and virology research.

Trial-Ready Liquid Biopsy-Optimizing Pre-Analytical Variables for ctDNA, cfRNA/miRNA, EVs & Proteins

Advancing Immunotherapy Testing with Functional Antigen Specific T Cells

Isolating, Characterizing & Utilizing Exosomes–Therapeutic, Diagnostic & Personal Care Applications

Overcoming Barriers in Drug Metabolism: Reaction Phenotyping Methods for Low Turnover Compound

10 Early signs of Dementia you are Missing!

Something is jamming GPS over Europe. Here's what we found

The French Do Not Care About Work

Ukraine's drone war is isolating Crimea

Ingeborga Dapkunaite: "They don't even know how happy I am"// "Tell Gordeeva"

The Incredible True Story of Patient Zero Richard Scolyer | 60 Minutes Australia

ADME 101: CYP3A4 Relative Induction Score (RIS) Opportunities & Interpretation

Golden Retriever Meets Completely Broken Rescue for the First Time
![Bukłaki [#21] Czy św. Faustynie naprawdę objawił się Jezus? || siostra Gaudia Skass](https://i.ytimg.com/vi/2l9eQV4hPGc/hqdefault.jpg?sqp=-oaymwEjCNACELwBSFryq4qpAxUIARUAAAAAGAElAADIQj0AgKJDeAE=&rs=AOn4CLADJsmyMp-Wc5cF6xpo5LTN8eOXpA)
Bukłaki [#21] Czy św. Faustynie naprawdę objawił się Jezus? || siostra Gaudia Skass

The Future of Medical Imaging: AI, Portability, and Patient Safety

What do tech pioneers think about the AI revolution? - The Engineers, BBC World Service

Colin Farrell Opens Up About His Son With Angelman Syndrome | PEOPLE

The most important lesson from 83,000 brain scans | Daniel Amen | TEDxOrangeCoast

From Biospecimen to Breakthrough: Powering Precision Biomarker Discovery with Disease-State Insights

Advancing DILI Assessment Using Micropatterned Co-Culture Models: HEPATOPAC® and HEPATOMUNE®

